- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Anticipation.
Displaying page 1 of 2.
EudraCT Number: 2020-005633-33 | Sponsor Protocol Number: 202000842 | Start Date*: 2021-06-02 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine | ||
Medical condition: A depressive disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004979-37 | Sponsor Protocol Number: 06-004 | Start Date*: 2006-10-27 |
Sponsor Name:MediQuest Therapeutics, Inc. | ||
Full Title: Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon | ||
Medical condition: Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-004857-27 | Sponsor Protocol Number: F20REWARDLU | Start Date*: 2008-01-02 |
Sponsor Name:Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich | ||
Full Title: Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone | ||
Medical condition: schizophrenic patients (F20.0, F20.1, F20.2, F20.3, F20.5, F20.6, F20.8, F20.9) and healthy controls | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001011-36 | Sponsor Protocol Number: ICO-A-2016-04 | Start Date*: 2017-05-24 | |||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
Full Title: Multicentric, comparative, randomized, open study comparing an early post-operative prophylactic non-invasive ventilation (NIV) to standard post-operative care in patients at high-risk of respir... | |||||||||||||
Medical condition: Legally adult patient going to have an operation under loco-regional or general anesthesia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004236-20 | Sponsor Protocol Number: MN4 | Start Date*: 2008-06-24 |
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA | ||
Full Title: PET-CT DIAGNOSIS OF CARCINOMA PROSTATICO WITH ALTERNATIVE TO FLUORODESOSSIGLUCOSIO Radio: 18F-COLINA | ||
Medical condition: Prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000237-17 | Sponsor Protocol Number: NL-80249 | Start Date*: 2022-12-15 |
Sponsor Name: | ||
Full Title: Prospective clinical trial to evaluate the efficacy of acetazolamide for the treatment of cystoid macular edema in inherited retinal dystrophies: the CAR trial | ||
Medical condition: Cystoid Macular Edema in inherited retinal dystrophies | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001890-83 | Sponsor Protocol Number: P03573 | Start Date*: 2006-03-09 |
Sponsor Name:Schering-Plough Research Institute | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor Anta... | ||
Medical condition: Subjects with symptoms of Coronary Heart Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) BE (Completed) IT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004378-92 | Sponsor Protocol Number: EdomTHC | Start Date*: 2019-05-27 | |||||||||||
Sponsor Name:Fundació Clínic per la Recerca Biomèdica | |||||||||||||
Full Title: Effect of cannabinoids (THC / CBD) on hyperalgesia in patients with deep endometriosis | |||||||||||||
Medical condition: Deep endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004919-11 | Sponsor Protocol Number: FLAIR-i | Start Date*: 2022-05-03 | ||||||||||||||||
Sponsor Name:Donders Institute for Brain, Cognition and Behaviour, Radboud University | ||||||||||||||||||
Full Title: The effect of colchicine on Food-reLAted effort-based decision making in brain and behavIouR in overweight and obesity: the FLAIR-i study. | ||||||||||||||||||
Medical condition: Low-grade inflammation in obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001739-38 | Sponsor Protocol Number: TAK-831-2001 | Start Date*: 2017-09-19 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001201-27 | Sponsor Protocol Number: P07038 | Start Date*: 2011-11-07 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA | ||
Full Title: A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blocka... | ||
Medical condition: not applicable | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) NL (Prematurely Ended) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001599-46 | Sponsor Protocol Number: F1J-MC-HMGI | Start Date*: 2017-05-09 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | ||
Medical condition: Generalized Anxiety Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-019983-35 | Sponsor Protocol Number: VPA-CdA | Start Date*: 2010-11-24 | |||||||||||
Sponsor Name:Cliniques universitaires Saint Luc | |||||||||||||
Full Title: Phase I-II study of low dose CdA combined with valproic acid (VPA) in previously treated B-cell chronic lymphocytic leukemia (CLL) patients. | |||||||||||||
Medical condition: •B-CLL, as defined by the NCIWG criteria •Patients must have intermediate or high-risk categories of the modified 3-stage Rai and Binet stagings | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003889-12 | Sponsor Protocol Number: 3 | Start Date*: 2022-01-20 |
Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red, M.P. (CIBER) | ||
Full Title: Prospective, multicenter and open study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments. | ||
Medical condition: Cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000342-60 | Sponsor Protocol Number: 190280 | Start Date*: 2016-06-21 | |||||||||||
Sponsor Name:Norfolk and Norwich University Hospital | |||||||||||||
Full Title: Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate | |||||||||||||
Medical condition: Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003671-60 | Sponsor Protocol Number: NO-CUT | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: TOTAL NEOADJUVANT TREATMENT WITHOUT SURGERY FOR LOCALLY ADVANCED RECTAL CANCER: PROSPECTIVE CLINICAL TRIAL TO ASSESS TUMOR COMPLETE RESPONSE, CIRCULATING TUMOR GENETIC AND EPIGENETIC BIOMARKERS, AN... | |||||||||||||
Medical condition: Adenocarcinoma of the medium/lower rectum in Stage II (cT3-4 N0) or Stage III (cT1-4, N1-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003176-40 | Sponsor Protocol Number: CHEMOCIM | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:AZIENDA USL TOSCANA NORD OVEST | |||||||||||||
Full Title: Randomised, clinical trial, controlled, open-label, multicenter, non-profit study to evaluate the superiority of a complementary treatment with additional Homeopathic Medicines and Acupuncture / Au... | |||||||||||||
Medical condition: Primary diagnosis of breast cancer (stage: I-III A) treated with adjuvant chemotherapy and / or endocrine therapy after surgical treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004897-32 | Sponsor Protocol Number: WO40324 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and... | |||||||||||||
Medical condition: Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) BE (Completed) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023263-18 | Sponsor Protocol Number: A0081105 | Start Date*: 2013-06-12 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | |||||||||||||
Medical condition: Primary Generalised Tonic Clonic Seizures | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) HU (Completed) LT (Completed) NL (Completed) SK (Completed) AT (Completed) BG (Completed) ES (Completed) PL (Completed) EE (Completed) GR (Completed) BE (Completed) HR (Completed) DK (Completed) PT (Not Authorised) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006152-34 | Sponsor Protocol Number: EFC6663 | Start Date*: 2007-11-28 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL | |||||||||||||
Medical condition: B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arising from CLL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) NL (Completed) FR (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
